CTVA vs ZTS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CTVA is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CTVA and ZTS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CTVA and ZTS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Corteva was formed in 2019 when DowDuPont spun off its agriculture business, and for most of its life it ran two segments: Seed (genetically improved corn, soybean, canola, and other crop seeds) and Crop Protection (herbicides, insecticides, fungicides, and biological products). That structure ended in October 2026, when Corteva completed the separation of its seed operations into a new independent company, Vylor Inc., which trades under the ticker VYLR. Corteva keeps the NYSE listing and the CTVA ticker as a crop protection and digital agriculture business, with a standalone revenue base reported at about $7.5 billion and projected 2025 EBITDA of about $1.4 billion. Headquartered in Indianapolis, Indiana. Chuck Magro has been CEO since 2021.

Full CTVA guide

Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs and cats) and livestock (cattle, swine, poultry, and fish). Spun out of Pfizer in 2013, it holds leading positions across dermatology, parasiticides, pain, vaccines, and other categories, with well-known franchises such as Apoquel and Cytopoint for pet itch and allergic skin conditions, the Simparica line of parasiticides, and Librela for osteoarthritis pain in dogs. Companion animal products, driven by the long-run humanization of pets and rising spending on their care, have become the larger and faster-growing part of the business, while livestock provides a more staple, protein-demand-linked base. Zoetis sells through veterinarians in the United States and internationally, invests heavily in research and development to sustain its innovation pipeline, and benefits from patents, brand loyalty, and deep vet relationships. Headquartered in Parsippany, New Jersey, it is widely viewed as a defensive-growth leader on the structural trend of people spending more on animal health, though it faces cyclical pet-visit softness, pricing pressure, and rising competition.

Full ZTS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CTVA drivers: A pure crop protection company after the Vylor spin-off; Biological products growth.
• ZTS drivers: Leader in a structurally growing market; Innovation-driven franchises and pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Commodity crop price cycles affect farmer purchasing power and Corteva revenue, and the company no longer has the seed business to cushion a weak chemistry year. For ZTS, zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted more than one guidance cut in 2026; analysts expect earnings to fall about 3% this year, with Q3 and Q4 EPS each projected about 11-12% lower than a year earlier.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CTVA if you believe its drivers more; ZTS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CTVA and ZTS guides.

CTVA. Post-spin Corteva is valued as a mid-cap crop chemicals company: about 11 times forward earnings and roughly $8.6 billion of market value, a long way from the premium the combined seed-and-chemistry company carried. Trailing figures on data sites (a P/E near 8, a dividend yield above 5%, TTM net income of ~$126 million) mix pre- and post-separation periods and per-share bases, so they are not a clean guide yet. UBS cut its price target to $15 from $90 with a Neutral rating; the cut tracks the smaller standalone company rather than a change in view, and the November 11, 2026 report will give the first clean standalone baseline.

ZTS. Zoetis has long been valued as a high-quality, defensive-growth compounder at a premium price-to-earnings multiple, but after the 2026 guidance cuts and a roughly 37% year-to-date decline it traded near 12 times forward earnings as of October 16, 2026, closer to a value multiple than its history. The market is pricing in stalled companion-animal growth, softer Librela demand and trade-down by pet owners, against still-high margins and about $2 billion of annual free cash flow. The 15 covering analysts have a mean target near $93.50, and the November 5, 2026 third-quarter report is the next test of whether the outlook has stabilized.

Headline figures (approximate, October 2026): CTVA shows standalone revenue base (crop protection and digital) ~$7.5 billion, per post-spin reports, standalone ebitda (2025, projected) ~$1.4 billion, operating margin (ttm, yahoo basis) ~13%, market cap ~$8.6 billion at $12.94 (Oct 16, 2026); ZTS shows revenue (ttm) ~$9.5 billion; Q2 2026 roughly flat YoY, q2 2026 revenue / adjusted eps ~$2.47 billion / ~$1.87 (vs ~$1.85 est.), operating / net margin (ttm) ~41% / ~28%, net income (ttm) ~$2.6 billion.

CTVA and ZTS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CTVA and ZTS exposure against your real portfolio. It is not an investment adviser.